# Small duct and large duct type intrahepatic cholangiocarcinoma reveal distinct patterns of immune signatures

**Authors:** Simon Bernatz, Falko Schulze, Julia Bein, Katrin Bankov, Scherwin Mahmoudi, Leon D. Grünewald, Vitali Koch, Angelika Stehle, Andreas A. Schnitzbauer, Dirk Walter, Fabian Finkelmeier, Stefan Zeuzem, Thomas J. Vogl, Peter J. Wild, Maximilian N. Kinzler

PMC · DOI: 10.1007/s00432-024-05888-y · 2024-07-22

## TL;DR

This study compares immune patterns in two types of liver cancer and identifies potential biomarkers for better diagnosis and treatment.

## Contribution

The study identifies novel immune-related biomarker candidates specific to small and large duct type intrahepatic cholangiocarcinoma.

## Key findings

- SD-iCCA showed strong downregulation of immune-related genes like DMBT1 and CEACAM6.
- LD-iCCA exhibited upregulation of CRP and complement-related genes.
- SD-iCCA had altered immune cell ratios and downregulated chemokine and cytokine pathways.

## Abstract

Dedicated gene signatures in small (SD-iCCA) and large (LD-iCCA) duct type intrahepatic cholangiocarcinoma remain unknown. We performed immune profiling in SD- and LD-iCCA to identify novel biomarker candidates for personalized medicine.

Retrospectively, 19 iCCA patients with either SD-iCCA (n = 10, median age, 63.1 years (45–86); men, 4) or LD-iCCA (n = 9, median age, 69.7 years (62–85); men, 5)) were included. All patients were diagnosed and histologically confirmed between 04/2009 and 01/2021. Tumor tissue samples were processed for differential expression profiling using NanoString nCounter® PanCancer Immune Profiling Panel.

With the exception of complement signatures, immune-related pathways were broadly downregulated in SD-iCCA vs. LD-iCCA. A total of 20 immune-related genes were strongly downregulated in SD-iCCA with DMBT1 (log2fc = -5.39, p = 0.01) and CEACAM6 (log2fc = -6.38, p = 0.01) showing the strongest downregulation. Among 7 strongly (log2fc > 2, p ≤ 0.02) upregulated genes, CRP (log2fc = 5.06, p = 0.02) ranked first, and four others were associated with complement (C5, C4BPA, C8A, C8B). Total tumor-infiltrating lymphocytes (TIL) signature was decreased in SD-iCCA with elevated ratios of exhausted-CD8/TILs, NK/TILs, and cytotoxic cells/TILs while having decreased ratios of B-cells/TILs, mast cells/TILs and dendritic cells/TILs. The immune profiling signatures in SD-iCCA revealed downregulation in chemokine signaling pathways inclulding JAK2/3 and ERK1/2 as well as nearly all cytokine-cytokine receptor interaction pathways with the exception of the CXCL1/CXCR1-axis.

Immune patterns differed in SD-iCCA versus LD-iCCA. We identified potential biomarker candidate genes, including CRP, CEACAM6, DMBT1, and various complement factors that could be explored for augmented diagnostics and treatment decision-making.

The online version contains supplementary material available at 10.1007/s00432-024-05888-y.

## Linked entities

- **Genes:** DMBT1 (deleted in malignant brain tumors 1) [NCBI Gene 1755], CEACAM6 (CEA cell adhesion molecule 6) [NCBI Gene 4680], CRP (C-reactive protein) [NCBI Gene 1401], C5 (complement C5) [NCBI Gene 727], C4BPA (complement component 4 binding protein alpha) [NCBI Gene 722], C8A (complement C8 alpha chain) [NCBI Gene 731], C8B (complement C8 beta chain) [NCBI Gene 732], JAK2 (Janus kinase 2) [NCBI Gene 3717], JAK3 (Janus kinase 3) [NCBI Gene 3718], MAPK3 (mitogen-activated protein kinase 3) [NCBI Gene 5595], MAPK1 (mitogen-activated protein kinase 1) [NCBI Gene 5594], CXCL1 (C-X-C motif chemokine ligand 1) [NCBI Gene 2919], CXCR1 (C-X-C motif chemokine receptor 1) [NCBI Gene 3577]
- **Diseases:** intrahepatic cholangiocarcinoma (MONDO:0003210)

## Full-text entities

- **Genes:** C8A (complement C8 alpha chain) [NCBI Gene 731], C8B (complement C8 beta chain) [NCBI Gene 732] {aka C82}, CEACAM6 (CEA cell adhesion molecule 6) [NCBI Gene 4680] {aka CD66c, CEAL, NCA, NCA-50/90}, CRP (C-reactive protein) [NCBI Gene 1401] {aka PTX1}, CXCR1 (C-X-C motif chemokine receptor 1) [NCBI Gene 3577] {aka C-C, C-C-CKR-1, CD128, CD181, CDw128a, CKR-1}, C4BPA (complement component 4 binding protein alpha) [NCBI Gene 722] {aka C4BP, PRP}, CD8A (CD8 subunit alpha) [NCBI Gene 925] {aka CD8, CD8alpha, IMD116, Leu2, p32}, DMBT1 (deleted in malignant brain tumors 1) [NCBI Gene 1755] {aka GP340, SAG, SALSA, muclin}, TNFRSF8 (TNF receptor superfamily member 8) [NCBI Gene 943] {aka CD30, D1S166E, Ki-1}, CXCL1 (C-X-C motif chemokine ligand 1) [NCBI Gene 2919] {aka FSP, GRO1, GROa, MGSA, MGSA-a, NAP-3}
- **Diseases:** SD-iCCA (MESH:D012735), intrahepatic cholangiocarcinoma (MESH:D018281), Tumor (MESH:D009369), mast cells (MESH:D000090362)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Figures

4 figures with captions in the complete paper: https://tomesphere.com/paper/PMC11271402/full.md

---
Source: https://tomesphere.com/paper/PMC11271402